David Gerber, M.D.

Assistant Professor

Department: Internal Medicine

Biography

David Gerber, M.D. is an Assistant Professor of Internal Medicine within the Hematology Oncology Division at UT Southwestern Medical Center, and Co-Director of the Phase I Laboratory Correlates Working Group.  He graduated cum laude from Yale University in New Haven, Connecticut, and his medical degree was obtained through Cornell University Medical College, New York, New York.  His internship and residency in Internal Medicine were completed at UT Southwestern Medical Center in Dallas, Texas with his fellowship in medical oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland.  Dr. Gerber is board certified in Internal Medicine and Medical Oncology and holds medical licenses in both Texas and Maryland.

 

Dr. Gerber is genuinely interested in Lung cancer and is highly active in his research pertaining to Lung cancer, including clinical trials.  His research has generated over 100 publications that he has authored or co-authored, including articles, abstracts, book chapters, books reviews and invited manuscripts.  His studies have contributed to invitations to lecture both nationally and internationally.

 

Dr. Gerber not only serves on a number of committees at UT Southwestern Medical Center, but he is also an active participant for the Lung Cancer Education Committee of the American Society of Clinical Oncology (ASCO) and the Career Development Committee with the International Association for the Study of Lung Cancer (IASLC).  He serves on the editorial board of the Journal of Clinical Oncology. Dr. Gerber holds memberships to several professional societies, and has been honored with numerous awards to include Best Doctors in Dallas, D Magazine, for the last two years.

Education

Medical School Weill Cornell Graduate School of Medical Science (2000)
Internship/Residency UT Southwestern Medical Center (2004), Internal Medicine
Fellowship Johns Hopkins Hospital (2007), Medical Oncology

Specialty Areas

Clinical Interests

  • Primary Interests
  • Endocrine Cancers
  • Head & Neck Cancer, Masses & Tumors
  • Mesothelioma
  • Pulmonary Cancer
  • Thoracic Cancer
  • Thymic Cancer
  • Thyroid Cancer, Masses & Tumors

Research Interests

  • Lung cancer, clinical and translational research
  • Oncology outcomes research

Publications

Featured Publications Legend

Featured Publications

The Incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention.

Gerber DE, Segal JB, Levy MY, Kane J, Jones RJ, Streiff MB. Blood 2008 May 14

Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center.

Yorio JT, Yan J, Xie Y, Gerber DE Clin Lung Cancer 2012 Nov 13 6 448-57

Stromal platelet-derived growth factor receptor a (PDGFRa) provides a therapeutic target independent of tumor cell PDGFRa expression in lung cancer xenografts.

Gerber DE, Gupta P, Dellinger MT, Toombs JE, Peyton M, Duignan I, Malaby J, Bailey T, Burns C, Brekken RA, Loizos N Mol. Cancer Ther. 2012 Nov 11 11 2473-82

Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer.

Gerber DE, Hamann HA, Rasco DW, Woodruff S, Lee SJ Patient education and counseling 2012 May

Consent timing and experience: modifiable factors that may influence interest in clinical research.

Gerber DE, Rasco DW, Skinner CS, Dowell JE, Yan J, Sayne JR, Xie Y J Oncol Pract 2012 Mar 8 2 91-6

How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience.

Taiwo EO, Yorio JT, Yan J, Gerber DE PLoS ONE 2012 7 12 e52313

Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors.

Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK Clin. Cancer Res. 2011 Nov 17 21 6888-96

Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy.

Gerber DE, Rasco DW, Le P, Yan J, Dowell JE, Xie Y J Thorac Oncol 2011 Feb 6 2 365-71

ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time.

Gerber DE, Minna JD Cancer Cell 2010 Dec 18 6 548-51

Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population.

Rasco DW, Yan J, Xie Y, Dowell JE, Gerber DE J Thorac Oncol 2010 Oct 5 10 1529-35

Results 1-10 of 14

Professional Associations/Affiliations

  • American Society of Clinical Oncology